What Is BEMER Therapy and Does It Actually Work?

BEMER therapy is a commercial device-based treatment that delivers weak pulsed electromagnetic fields to the body, marketed primarily as a way to improve blood flow in the smallest blood vessels. Whether it “works” depends heavily on what you expect it to do. For a handful of conditions, particularly fatigue in people with multiple sclerosis, there is modest evidence of benefit. For the broader claims that populate BEMER marketing materials, including pain relief, athletic recovery, and general wellness enhancement, the peer-reviewed evidence is either thin, mixed, or outright negative. The gap between what BEMER’s manufacturer suggests and what controlled trials actually show is one of the widest in the wellness-device space.

What the Device Actually Does

BEMER stands for Bio-Electro-Magnetic-Energy-Regulation. The device consists of a mat, pad, or applicator that generates a low-frequency pulsed electromagnetic field at an intensity below 35 microtesla, which is far weaker than an MRI scanner and weaker even than the Earth’s own magnetic field at the surface.¹ The manufacturer’s central claim is that this specific signal pattern stimulates vasomotion, the rhythmic contraction and relaxation of tiny arterioles that helps push blood through capillary beds. A typical session lasts eight to twenty minutes, during which you lie on the mat or apply a smaller pad to a specific body area. The manufacturer sells both consumer units (costing roughly $4,000 to $6,000) and professional models for clinics.

The idea behind it is straightforward: if you can coax those tiny blood vessels into pumping more rhythmically, you improve local blood supply, oxygen delivery, and waste removal in tissues. That is a plausible biological premise. The question is whether this particular device, at this particular intensity, actually achieves that in a way that matters clinically.

The Microcirculation Claim

The strongest and most frequently repeated marketing claim is that BEMER measurably improves microcirculation. There is some laboratory-level support for this. One study of elderly rehabilitation patients found that the BEMER signal increased spontaneous arteriolar vasomotion by about 20% compared to controls, along with changes in blood distribution within microvascular networks and venular oxygen use.² That sounds promising, but context matters. The same study noted that the effect was smaller in stressed middle-aged subjects and faded over time.

A more rigorous study measuring cutaneous blood flow in healthy volunteers told a less encouraging story. Both the BEMER group and the control group showed significant increases in blood flow, mixed venous oxygen saturation, and venous hemoglobin during the experiment compared to baseline. When the two groups were compared to each other, their measurements did not differ, except that the control group actually had higher flow values at one time point.³ In plain terms, the improvements seemed to come from lying down and resting, not from the electromagnetic signal itself.

A similar pattern appeared in a study measuring lymphatic flow during microsurgery. A single two-minute BEMER application produced no significant change in lymphatic flow, while manual lymphatic drainage increased it substantially.⁴ This does not necessarily mean BEMER has zero vascular effects under all circumstances, but it suggests the effect, if present, is small enough that it does not reliably show up when pitted against a sham device or compared to simple hands-on techniques.

Musculoskeletal Pain

Pain relief is probably the most common reason people buy or seek out BEMER therapy. Practitioners and users report improvements in back pain, knee pain, and general musculoskeletal discomfort. But the most comprehensive look at this evidence is sobering. A systematic review of randomized controlled trials examining BEMER for musculoskeletal pain found that while some studies reported pain reductions after BEMER treatment, only one out of four sham-controlled trials found BEMER to be superior to sham treatment. The review concluded that the current evidence does not demonstrate BEMER therapy is more effective than placebo for reducing musculoskeletal pain.⁵

This is an important distinction. Many individual trials show that people feel better after using BEMER, but those same trials often show that people feel better after using a deactivated BEMER device too. That is the placebo effect doing its thing, and it is powerful for subjective outcomes like pain. The real test is whether the active device beats the inactive one, and for pain, it largely does not.

One large double-blind trial on chronic low back pain illustrates this well. Patients received either real BEMER therapy or sham therapy alongside exercise, three to five times a week for 13 weeks. Both groups improved. Pain intensity showed no statistically significant difference between the groups at any assessment point. There was a brief advantage for the BEMER group in physical disability scores at week three, but it did not persist. The study concluded that while BEMER therapy improved outcomes for chronic low back pain patients, it was not superior to other treatment options.⁶

A separate pilot study did find significant improvement in resting pain scores and fatigue for people with low back pain after BEMER combined with physiotherapy, but the same study found no significant improvement in any parameter for people with knee complaints.⁷ The inconsistency across body sites, outcomes, and studies makes it hard to build a confident case for BEMER as a pain treatment.

Multiple Sclerosis Fatigue

This is where the BEMER evidence looks its best. Fatigue is one of the most debilitating and difficult-to-treat symptoms of multiple sclerosis, and a small body of research suggests BEMER may help with it. A randomized, double-blind trial found that after 12 weeks of BEMER therapy, patients with MS reported significantly lower fatigue scores compared to the placebo group on two different fatigue scales. Physical and cognitive fatigue both improved. The catch: by six weeks after treatment stopped, the difference between groups had disappeared.⁸

A follow-up study tracked what happened when the placebo group crossed over to receive real BEMER therapy. Those patients experienced significant reductions in fatigue after switching, and participation in BEMER treatment turned out to be the strongest predictor of lower fatigue at long-term follow-up.⁹ That crossover design adds some confidence that the effect is real, since the same individuals served as their own controls.

A recent systematic review and meta-analysis that pooled data from multiple trials of pulsed electromagnetic field therapy for MS fatigue found a statistically significant reduction in fatigue severity compared to sham, though the effect size was small.¹⁰ “Statistically significant but small” is a fair summary. It is enough to warrant further research and perhaps enough that an MS patient dealing with severe fatigue might consider it as one tool among many, but it is not a dramatic treatment effect.

Athletic Performance and Recovery

BEMER has made significant inroads into professional and amateur sports, with endorsements from athletes and sponsorship deals that give it high visibility. The claim is that BEMER sessions before or after exercise improve performance, speed recovery, and reduce soreness. The controlled evidence does not support this.

A study examining BEMER’s effect on repeated high-intensity sprints found no difference in peak power, average power, fatigue index, or total work performed between BEMER recovery, passive recovery, and active recovery. Active recovery (light movement between sprints) actually led to a more comfortable experience, with decreased pain intensity and unpleasantness ratings, while BEMER recovery saw pain ratings increase, comparable to simply sitting still.¹¹ Getting up and walking around between bouts of hard exercise worked better than the $5,000 mat.

One area that did produce a positive signal was sleep quality in elite athletes. A study of players in Norwegian women’s football found that subjective sleep duration and sleep quality both increased significantly during the period when players were using BEMER therapy compared to a control period. Game nights still disrupted sleep regardless of BEMER use, but overall sleep metrics were better during the treatment phase.¹² The finding is interesting but relies on subjective self-reported sleep rather than polysomnography, and a single study in one group of athletes is a thin basis for broad claims about sleep improvement.

Why the Research Picture Is So Murky

Several structural problems make it difficult to draw firm conclusions about BEMER. The systematic review on musculoskeletal pain noted considerable heterogeneity in treatment protocols across the included trials. Different studies used different session lengths, frequencies, durations, and body sites. That inconsistency makes it hard to compare results and nearly impossible to determine whether a “correct” dose exists that might work better than the ones tested.

Many of the positive studies were small pilot trials, often with fewer than 50 participants per arm. Small studies are more prone to producing false positives and to showing exaggerated effect sizes. When larger or better-controlled studies are conducted on the same questions, the effects tend to shrink or vanish, as happened with the chronic low back pain trial.

There is also a funding and affiliation issue common in the device therapy space. Several of the studies on BEMER were conducted by researchers with ties to the company or were supported by the manufacturer. That does not automatically invalidate the findings, but it is a pattern that tends to inflate positive results across all areas of medicine, not just BEMER. Independent replication by researchers without commercial connections would be far more convincing.

The wound healing evidence illustrates the problem at its most extreme. Published case reports describe dramatic healing of leg ulcers with intensive BEMER therapy (five to ten sessions per day), but these are individual patient stories without control groups, blinding, or any way to separate the BEMER effect from the concurrent medical care patients were receiving.¹³ Case reports are the lowest tier of clinical evidence. They can generate hypotheses worth testing but cannot establish that a treatment works.

The Placebo Problem for Device Therapies

BEMER occupies a tricky space because the device itself is physically real: it sits on your body, you feel warmth from lying on it, and there is a control panel with settings. This creates a strong placebo context. People who spend thousands of dollars on a medical-feeling device, set aside time to lie still on it daily, and believe it is improving their circulation are primed to feel better. And many of them genuinely do feel better, which is why anecdotal reports are overwhelmingly positive while sham-controlled trials are mostly neutral.

The chronic low back pain trial is a textbook example. Both groups improved substantially over 13 weeks. Exercise therapy, the passage of time, attention from therapists, and the ritual of treatment all contributed.⁶ The electromagnetic signal itself did not add a detectable benefit to that package. For someone considering BEMER, this raises a practical question: if the ritual of lying still and relaxing twice a day produces most of the improvement, do you need a $5,000 device to get it?

Safety Considerations

On the safety front, BEMER appears to be low-risk. The electromagnetic fields it generates are extremely weak, well below the thresholds that regulatory agencies consider hazardous. None of the clinical trials reviewed reported serious adverse events attributable to the device. The main risk is financial: spending several thousand dollars on a device that may not outperform a daily rest break. BEMER is classified as a consumer wellness device, not a medical device approved for treating specific diseases. The FDA has cleared it as a Class I device, which is the lowest-risk category and does not require demonstration of clinical efficacy. That clearance means the FDA considers it unlikely to cause harm; it does not mean the FDA considers it effective for any medical condition.

People with implanted electronic devices like pacemakers or insulin pumps are generally advised to avoid pulsed electromagnetic field devices of any kind, as a precaution against signal interference. Pregnant women are also typically told to avoid them, though this is based on the precautionary principle rather than evidence of harm.

How BEMER Compares to Other PEMF Devices

BEMER is far from the only pulsed electromagnetic field device on the market. Dozens of PEMF mats, pads, and applicators exist at various price points, some costing a fraction of what BEMER charges. BEMER’s primary marketing differentiator is its proprietary signal pattern, which the company claims is uniquely effective at stimulating vasomotion. Whether that specific waveform is meaningfully different from other PEMF signals in clinical terms remains unproven. The broader PEMF literature contains a wider range of studies, some showing benefit for bone healing (FDA-cleared PEMF devices have been used for non-union fractures since the 1970s) and some showing benefit for osteoarthritis pain. But those findings come from devices with different signal characteristics and intensities, and they cannot be directly transferred to BEMER.

The meta-analysis on MS fatigue grouped PEMF therapies together and found a small positive effect across the category, not specifically for BEMER’s waveform versus others.¹⁰ This makes it hard to justify BEMER’s premium price on the grounds that its signal is uniquely effective. If PEMF therapy helps with MS fatigue, it might not matter which brand delivers the signal.

What Practitioners and Users Should Know

If you are considering BEMER therapy, the honest assessment looks like this. For MS fatigue, there is some controlled evidence that it helps, though the effect is modest and appears to require ongoing use. For musculoskeletal pain, the evidence does not support it over placebo when properly controlled. For athletic performance and recovery, it does not appear to do anything a simple active recovery does not do better. For wound healing and general wellness, the evidence is anecdotal.

The heart rate variability data from coronary heart disease patients is intriguing at a physiological level but has not translated into demonstrated clinical benefits for cardiovascular outcomes.¹ A device that produces a measurable change on a physiological parameter is not the same as a device that makes people healthier or less symptomatic. Many interventions move lab values without moving outcomes that patients care about.

The broader wellness device market is full of products that occupy this space: plausible mechanism, weak evidence, expensive hardware, strong anecdotal support. BEMER is neither the most dubious nor the most supported product in that category. What sets it apart is the volume of its clinical research program. More trials have been conducted on BEMER than on most competing devices, and the company deserves credit for subjecting its product to sham-controlled testing at all. The problem is that those trials have mostly failed to show the device outperforms a convincing placebo. For a product at this price point, that is a finding worth taking seriously.

1
PubMed Central. Physical Vascular Therapy (BEMER) Affects Heart Rate Asymmetry in Patients With Coronary Heart Disease
2
European Journal of Integrative Medicine. Complementary therapeutic effects of definite alternating electromagnetic fields upon local regulating mechanism of microcirculation
3
PubMed. The influence of pulsed electromagnetic field therapy (PEMFT) on cutaneous blood flow in healthy volunteers
4
PubMed. The Influence of Pulsed Electromagnetic Field Therapy on Lymphatic Flow During Supermicrosurgery
5
Wiley Online Library. Efficacy of Bio-Electro-Magnetic-Energy-Regulation Therapy in Musculoskeletal Pain Management: A Systematic Review of Randomized Controlled Trials
6
PubMed Central. Efficacy of Pulsed Low-Frequency Magnetic Field Therapy on Patients with Chronic Low Back Pain: A Randomized Double-Blind Placebo-Controlled Trial
7
PubMed Central. BEMER Therapy Combined with Physiotherapy in Patients with Musculoskeletal Diseases: A Randomised, Controlled Double Blind Follow-Up Pilot Study
8
PubMed. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial
9
PubMed. Long-term effects of Bio-Electromagnetic-Energy Regulation therapy on fatigue in patients with multiple sclerosis
10
PubMed. Efficacy and safety of pulsed electromagnetic field therapy for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis
11
PubMed. The Effects of Physical BEMER Vascular Therapy on Work Performed During Repeated Wingate Sprints
12
Frontiers in Sports and Active Living. The effect of electro-magnetic-energy-regulation therapy on subjective sleep among elite players in Norwegian women’s football
13
Biomedical Journal of Scientific & Technical Research. Development of an Oxygen Pressure Therapy Device System Combined with BEMER® Therapy for the Treatment of Leg Ulcers